Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches
Cancers · 19.06.2023 · 15 (12) · 3245
DOI: 10.3390/cancers15123245 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.06.2023. Verfasst von Sara Salucci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40126 Bologna, Italy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer (LC) is the second most common neoplasm in men and the third most common in women. In the last decade, LC therapies have undergone significant improvements with the advent of immunotherapy. However, the effectiveness of the available treatments remains insufficient due to the presence of therapy-resistant cancer cells. For decades, chemotherapy and radiotherapy have dominated the treatment strategy for LC; however, relapses occur rapidly and result in poor survival. Malignant lung tumors are classified as either small- or non-small-cell lung carcinoma (SCLC and NSCLC). Despite improvements in the treatment of LC in recent decades, the benefits of surgery, radiotherapy, and chemotherapy are limited, although they have improved the prognosis of LC despite the persistent low survival rate due to distant metastasis in the late stage. The identification of novel prognostic molecular markers is crucial to understand the underlying mechanisms of LC initiation and progression. The potential role of phosphatidylinositol in tumor growth and the metastatic process has recently been suggested by some researchers. Phosphatidylinositols are lipid molecules and key players in the inositol signaling pathway that have a pivotal role in cell cycle regulation, proliferation, differentiation, membrane trafficking, and gene expression. In this review, we discuss the current understanding of phosphoinositide-specific phospholipase enzymes and their emerging roles in LC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40126 Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy.
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
- "Luigi Luca Cavalli-Sforza'' Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerca (IGM-CNR), 40136 Bologna, Italy.
- IRCCS, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
ORCID-Profile: Sara Salucci, Beatrice Aramini, William Blalock, Irene Faenza
Zitieren
APA
Salucci, S., Aramini, B., Bartoletti-Stella, A., Versari, I., Martinelli, G., Blalock, W., Stella, F., & Faenza, I. (2023). Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches. Cancers, 15(12), 3245. https://doi.org/10.3390/cancers15123245
Vancouver
Salucci S, Aramini B, Bartoletti-Stella A, Versari I, Martinelli G, Blalock W, et al. Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches. Cancers. 2023;15(12):3245. doi:10.3390/cancers15123245
BibTeX
@article{Salucci2023,
author = {Salucci, Sara and Aramini, Beatrice and Bartoletti-Stella, Anna and Versari, Ilaria and Martinelli, Giovanni and Blalock, William and Stella, Franco and Faenza, Irene},
title = {Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches},
journal = {Cancers},
year = {2023},
volume = {15},
number = {12},
pages = {3245},
doi = {10.3390/cancers15123245}
}
EUVIMED